Loading...
70 favipiravir COVID-19 controlled studies, 34 RCTs
17% improvement
for early treatment, RR
0.83
[0.61-1.12]
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ruzhentsova (RCT)
6%
0.94 [0.78-1.14]
hosp.
3/112
2/56
Improvement, RR [CI]
Treatment
Control
Ruzhentsova (RCT)
39%
0.61 [0.43-0.88]
no recov.
112 (n)
56 (n)
Ruzhentsova (RCT)
22%
0.78 [0.92-1.79]
viral+
112 (n)
56 (n)
Udwadia (RCT)
66%
0.34 [0.01-8.12]
death
0/73
1/75
Udwadia (RCT)
29%
0.71 [0.49-1.03]
no recov.
75 (n)
72 (n)
Udwadia (RCT)
43%
0.57 [0.36-0.91]
no recov.
75 (n)
72 (n)
Udwadia (RCT)
27%
0.73 [0.51-1.06]
viral time
75 (n)
72 (n)
Sawanpanyalert
68%
0.32 [0.15-0.66]
progression
n/a
n/a
Holubar (DB RCT)
89%
0.11 [0.01-2.02]
hosp.
0/75
4/74
Holubar (DB RCT)
30%
0.70 [0.23-2.12]
ER visit
5/75
7/74
Holubar (DB RCT)
-19%
1.19 [0.78-1.85]
no recov.
65 (n)
70 (n)
Holubar (DB RCT)
-32%
1.32 [0.83-2.08]
viral+
59 (n)
57 (n)
Alattar (PSM)
33%
0.67 [0.28-1.61]
death
8/387
12/387
Alattar (PSM)
-2%
1.02 [0.90-1.16]
no recov.
26/387
28/387
Alattar (PSM)
-6%
1.06 [0.99-1.14]
recov. time
387 (n)
387 (n)
Alattar (PSM)
44%
0.56 [0.44-0.71]
viral+
78/387
139/387
Bosaeed (DB RCT)
-619%
7.19 [0.38-138]
ICU
3/112
0/119
Bosaeed (DB RCT)
-219%
3.19 [0.66-15.5]
hosp.
6/112
2/119
Bosaeed (DB RCT)
-12%
1.12 [0.80-1.56]
no recov.
112 (n)
119 (n)
Bosaeed (DB RCT)
-15%
1.15 [0.75-1.75]
viral+
112 (n)
119 (n)
FLARE
Lowe (DB RCT)
-202%
3.02 [0.13-72.6]
ICU
1/59
0/60
FLARE
Lowe (DB RCT)
-202%
3.02 [0.13-72.6]
hosp.
1/59
0/60
FLARE
Lowe (DB RCT)
28%
0.72 [0.44-0.98]
viral+
29/54
38/52
Adhikari (RCT)
-40%
1.40 [0.57-3.44]
no improv.
10/38
6/32
Adhikari (RCT)
-36%
1.36 [0.52-3.59]
no improv.
8/27
5/23
Adhikari (RCT)
-64%
1.64 [0.18-15.3]
no improv.
2/11
1/9
Tsuzuki
13%
0.87 [0.52-1.46]
death
2,532 (n)
5,122 (n)
Tsuzuki
-2%
1.02 [0.65-1.60]
ventilation
2,532 (n)
5,122 (n)
Tsuzuki
18%
0.82 [0.66-1.04]
progression
2,532 (n)
5,122 (n)
Qadir
97%
0.03 [0.00-0.47]
death
0/125
17/125
Qadir
60%
0.40 [0.23-0.71]
hosp.
14/125
35/125
Qadir
97%
0.03 [0.00-0.47]
no recov.
0/125
17/125
Qadir
71%
0.29 [0.17-0.50]
no recov.
14/125
48/125
Qadir
79%
0.21 [0.13-0.36]
no recov.
14/125
66/125
Qadir
71%
0.29 [0.22-0.40]
no recov.
32/125
109/125
Qadir
58%
0.42 [0.25-0.70]
recov. time
125 (n)
125 (n)
Usanma Koban
86%
0.14 [0.02-0.70]
viral+
47 (n)
79 (n)
Sirijatuphat (RCT)
64%
0.36 [0.20-0.64]
improv.
62 (n)
31 (n)
Sirijatuphat (RCT)
90%
0.10 [0.03-0.39]
improv.
62 (n)
31 (n)
Sirijatuphat (RCT)
43%
0.57 [0.23-1.43]
progression
8/62
7/31
Sirijatuphat (RCT)
-4%
1.04 [0.63-1.72]
viral+
62 (n)
31 (n)
McMahon (RCT)
-1%
1.01 [0.34-3.03]
oxygen
6/99
6/100
McMahon (RCT)
-56%
1.56 [0.71-3.43]
hosp.
14/99
9/99
PRESECO
Golan (DB RCT)
67%
0.33 [0.01-8.12]
death
0/599
1/588
PRESECO
Golan (DB RCT)
2%
0.98 [0.43-2.25]
progression
11/599
11/588
PRESECO
Golan (DB RCT)
7%
0.93 [0.77-1.12]
progression
159/599
168/588
PRESECO
Golan (DB RCT)
4%
0.96 [0.71-1.29]
no recov.
73/599
75/588
PRESECO
Golan (DB RCT)
14%
0.86 [0.81-0.91]
viral time
140 (n)
132 (n)
Bruminhent
-227%
3.27 [1.43-7.50]
progression
n/a
n/a
Chandiwana (RCT)
-13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Chandiwana (RCT)
-23%
1.23 [0.73-2.08]
recov. time
37 (n)
39 (n)
CT2
Chandiwana (RCT)
-67%
1.67 [0.85-3.23]
viral+
27/37
25/38
CT2
Vaezi (DB RCT)
-105%
2.05 [0.40-10.6]
hosp.
4/38
2/39
PLATCOV
Luvira (RCT)
-6%
1.06 [0.93-1.21]
viral rate
116 (n)
132 (n)
Lokanuwatsatien
14%
0.86 [0.64-1.17]
PASC
400 (n)
402 (n)
Iwata (DB RCT)
-16%
1.16 [0.45-2.21]
oxygen
12/43
12/43
Iwata (DB RCT)
19%
0.81 [0.17-2.28]
oxygen
5/24
6/22
Iwata (DB RCT)
-16%
1.16 [0.74-1.82]
viral+
21/41
19/43
Iwata (DB RCT)
6%
0.94 [0.69-1.28]
viral+
26/41
29/43
Iwata (DB RCT)
1%
0.99 [0.82-1.20]
viral+
34/41
36/43
Iwata (DB RCT)
6%
0.94 [0.82-1.09]
viral+
36/41
40/43
Cai
69%
0.31 [0.10-0.96]
pneumonia
35 (n)
45 (n)
Cai
71%
0.29 [0.10-0.86]
viral+
35 (n)
45 (n)
Ivashchenko (RCT)
-300%
4.00 [0.20-79.6]
death
2/40
0/20
Ivashchenko (RCT)
-300%
4.00 [0.20-79.6]
ventilation
2/40
0/20
Ivashchenko (RCT)
-300%
4.00 [0.20-79.6]
ICU
2/40
0/20
Ivashchenko (RCT)
46%
0.54 [0.33-0.88]
viral+
15/40
14/20
Ivashchenko (RCT)
62%
0.38 [0.09-1.52]
viral+
3/40
4/20
Ivashchenko (RCT)
-67%
1.67 [0.52-5.39]
no disch.
10/40
3/20
Lou (RCT)
-422%
5.22 [0.28-96.2]
ICU
2/9
0/10
Lou (RCT)
11%
0.89 [0.34-2.32]
no recov.
4/9
5/10
Lou (RCT)
14%
0.86 [0.58-1.30]
no recov.
7/9
9/10
Lou (RCT)
-422%
5.22 [0.28-96.2]
viral+
2/9
0/10
Lou (RCT)
-11%
1.11 [0.47-2.60]
viral+
5/9
5/10
Pushkar (RCT)
14%
0.86 [0.73-1.00]
no recov.
73/100
85/100
Pushkar (RCT)
33%
0.67 [0.54-0.82]
recov. time
100 (n)
100 (n)
Pushkar (RCT)
45%
0.55 [0.42-0.72]
no recov.
40/100
73/100
Pushkar (RCT)
20%
0.80 [0.64-1.00]
recov. time
100 (n)
100 (n)
Pushkar (RCT)
70%
0.30 [0.16-0.58]
no disch.
10/100
33/100
Pushkar (RCT)
27%
0.73 [0.63-0.86]
no recov.
66/100
90/100
Pushkar (RCT)
33%
0.67 [0.50-0.89]
pneumonia
40/100
60/100
Pushkar (RCT)
90%
0.10 [0.02-0.40]
viral+
2/100
21/100
Khamis (RCT)
15%
0.85 [0.28-2.59]
death
5/44
6/45
OT1 CT2
Khamis (RCT)
-2%
1.02 [0.42-2.48]
ICU
8/44
8/45
OT1 CT2
Khamis (RCT)
-10%
1.10 [0.60-1.99]
no recov.
15/44
14/45
OT1 CT2
Solaymani.. (RCT)
-19%
1.19 [0.70-2.04]
death
26/190
21/183
OT1
Solaymani.. (RCT)
-53%
1.53 [0.86-2.71]
ventilation
27/190
17/183
OT1
Solaymani.. (RCT)
-19%
1.19 [0.73-1.94]
ICU
31/190
25/183
OT1
Zhao (RCT)
59%
0.41 [0.16-1.03]
viral+
7/36
9/19
Zhao (RCT)
52%
0.48 [0.25-0.91]
viral time
36 (n)
19 (n)
Haji Aghajani
26%
0.74 [0.43-1.27]
death
40 (n)
951 (n)
Alamer
-56%
1.56 [0.73-3.36]
death
12/233
21/223
Alamer
90%
0.10 [0.04-0.29]
ventilation
4/218
27/165
Alamer
49%
0.51 [0.41-0.64]
no disch.
221 (n)
201 (n)
Almoosa
-42%
1.42 [0.90-2.25]
death
33/110
24/116
Almoosa
-149%
2.49 [1.29-4.80]
death
26/110
11/116
Almoosa
62%
0.38 [0.13-1.17]
death
4/110
11/116
Almoosa
-90%
1.90 [1.11-3.26]
ICU
110 (n)
116 (n)
Almoosa
-11%
1.11 [0.96-1.29]
recov. time
110 (n)
116 (n)
Shinkai (SB RCT)
37%
0.63 [0.40-0.98]
imp. time
107 (n)
49 (n)
Shinkai (SB RCT)
59%
0.41 [0.18-0.93]
imp. time
47 (n)
13 (n)
Assiri (ICU)
-79%
1.79 [0.33-8.02]
death
11/67
3/51
ICU patients
Kulzhanova
88%
0.12 [0.04-0.37]
no improv.
3/40
25/40
Kulzhanova
89%
0.11 [0.01-2.00]
no improv.
0/40
4/40
Kulzhanova
50%
0.50 [0.21-1.20]
viral+
6/40
12/40
Chen (RCT)
-3%
1.03 [0.15-7.22]
ICU
2/116
2/120
OT1
Chen (RCT)
74%
0.26 [0.03-2.28]
resp. failure
1/116
4/120
OT1
Chen (RCT)
20%
0.80 [0.48-1.34]
oxygen
21/116
27/120
OT1
Chen (RCT)
70%
0.30 [0.10-0.87]
dyspnea
4/116
14/120
OT1
Chen (RCT)
10%
0.90 [0.45-1.80]
dyspnea
13/116
15/120
OT1
Chen (RCT)
20%
0.80 [0.60-1.08]
no recov.
45/116
58/120
OT1
Alotaibi
57%
0.43 [0.18-1.01]
death
244 (n)
193 (n)
OT1
Tabarsi (RCT)
30%
0.70 [0.17-2.88]
death
3/32
4/30
OT1
Tabarsi (RCT)
41%
0.59 [0.22-1.59]
ICU
5/32
8/30
OT1
Tabarsi (RCT)
6%
0.94 [0.72-1.23]
CT imp.
24/32
24/30
OT1
Tabarsi (RCT)
25%
0.75 [0.58-0.97]
hosp. time
32 (n)
30 (n)
OT1
FIGHT-COVID-19
Atipornwa.. (RCT)
23%
0.77 [0.35-1.67]
death
10/100
13/100
OT1 CT2
FIGHT-COVID-19
Atipornwa.. (RCT)
60%
0.40 [0.20-0.79]
progression
10/100
25/100
OT1 CT2
FIGHT-COVID-19
Atipornwa.. (RCT)
9%
0.91 [0.73-1.14]
viral time
50 (n)
50 (n)
OT1 CT2
FIGHT-COVID-19
Atipornwa.. (RCT)
9%
0.91 [0.75-1.10]
viral time
50 (n)
50 (n)
OT1 CT2
Damayanti
54%
0.46 [0.22-0.92]
no recov.
96 (n)
96 (n)
Shenoy (DB RCT)
-29%
1.29 [0.60-2.77]
death
14/175
11/178
Shenoy (DB RCT)
-33%
1.33 [0.67-2.66]
ventilation
17/175
13/178
Shenoy (DB RCT)
-2%
1.02 [0.57-1.82]
ICU
20/175
20/178
Shenoy (DB RCT)
-1%
1.01 [0.78-1.30]
no recov.
157 (n)
158 (n)
Shenoy (DB RCT)
6%
0.94 [0.75-1.18]
no recov.
175 (n)
178 (n)
Shenoy (DB RCT)
17%
0.83 [0.58-1.18]
no recov.
157 (n)
158 (n)
Shenoy (DB RCT)
32%
0.68 [0.50-0.93]
no recov.
175 (n)
178 (n)
Chuah (RCT)
-1154%
12.54 [0.76-208]
death
5/250
0/250
Chuah (RCT)
-20%
1.20 [0.36-3.97]
ventilation
6/250
5/250
Chuah (RCT)
-9%
1.09 [0.49-2.31]
ICU
13/250
12/250
Finberg (RCT)
-200%
3.00 [0.13-70.3]
death
1/25
0/25
Finberg (RCT)
-200%
3.00 [0.13-70.3]
ventilation
1/25
0/25
Finberg (RCT)
58%
0.42 [0.16-1.10]
no recov.
25 (n)
25 (n)
Finberg (RCT)
-46%
1.46 [0.45-4.81]
no recov.
25 (n)
25 (n)
Finberg (RCT)
47%
0.53 [0.29-0.98]
viral time
25 (n)
25 (n)
Al Mutair (ICU)
7%
0.93 [0.77-1.12]
death
119/269
128/269
ICU patients OT1
Al Mutair (ICU)
-9%
1.09 [0.82-1.43]
ARDS
76/269
70/269
ICU patients OT1
Al Mutair (ICU)
-34%
1.34 [1.13-1.59]
ICU
269 (n)
269 (n)
ICU patients OT1
Al Mutair (ICU)
-37%
1.37 [1.14-1.64]
hosp. time
269 (n)
269 (n)
ICU patients OT1
Kurniyanto
48%
0.52 [0.22-1.25]
death
10/325
9/152
Cilli
38%
0.62 [0.24-1.63]
death
5/23
8/23
Al-Muhsen
-263%
3.63 [1.06-12.4]
death
156 (n)
442 (n)
Al-Muhsen
41%
0.59 [0.47-0.75]
oxygen
52/156
248/442
Al-Muhsen
-40%
1.40 [1.03-1.91]
hosp. time
156 (n)
442 (n)
Yulia
85%
0.15 [0.02-1.02]
death
432 (all patients)
Uyaroğlu (PSM)
67%
0.33 [0.01-7.96]
death
0/42
1/42
OT1
Uyaroğlu (PSM)
-200%
3.00 [0.13-71.6]
ICU
1/42
0/42
OT1
Uyaroğlu (PSM)
-11%
1.11 [0.24-5.08]
hosp. time
42 (n)
42 (n)
OT1
AlQahtani (RCT)
-196%
2.96 [0.12-71.1]
death
1/54
0/52
AlQahtani (RCT)
76%
0.24 [0.03-2.08]
ICU
1/54
4/52
AlQahtani (RCT)
-42%
1.42 [0.50-4.04]
no recov.
8/53
5/47
AlQahtani (RCT)
43%
0.57 [0.27-1.21]
viral+
8/40
14/40
Shinada
7%
0.93 [0.45-1.89]
hosp.
17 (n)
17 (n)
Shinada
55%
0.45 [0.21-0.96]
viral+
17 (n)
17 (n)
Hassaniazad (RCT)
68%
0.32 [0.07-1.48]
death
2/32
6/31
OT1
Hassaniazad (RCT)
3%
0.97 [0.06-14.8]
death
1/32
1/31
OT1
Hassaniazad (RCT)
35%
0.65 [0.20-2.07]
ICU
4/32
6/31
OT1
Hassaniazad (RCT)
25%
0.75 [0.51-1.10]
hosp. time
32 (n)
31 (n)
OT1
Hassaniazad (RCT)
18%
0.82 [0.62-1.08]
viral+
22/32
26/31
OT1
Hafez
-3%
1.03 [0.68-1.56]
viral+
59 (n)
1,446 (n)
CT2
Hafez
59%
0.41 [0.15-1.15]
viral+
4 (n)
1,446 (n)
CT2
Rahman (DB RCT)
89%
0.11 [0.01-0.75]
no improv.
1/19
8/16
Rahman (DB RCT)
65%
0.35 [0.16-0.78]
no improv.
5/19
12/16
Rahman (DB RCT)
47%
0.53 [0.34-0.81]
no improv.
10/19
16/16
Rahman (DB RCT)
92%
0.08 [0.01-0.59]
viral+
1/25
12/25
Rahman (DB RCT)
62%
0.38 [0.18-0.80]
viral+
6/25
16/25
Rahman (DB RCT)
48%
0.52 [0.36-0.76]
viral+
13/25
25/25
Tehrani (RCT)
34%
0.66 [0.34-1.26]
hosp.
10/38
16/40
Tehrani (RCT)
80%
0.20 [0.01-4.12]
no recov.
0/38
2/40
Tehrani (RCT)
58%
0.42 [0.21-0.84]
no recov.
8/38
20/40
Tehrani (RCT)
47%
0.53 [0.05-5.57]
no recov.
1/38
2/40
Tehrani (RCT)
47%
0.53 [0.20-1.40]
no recov.
5/38
10/40
Tehrani (RCT)
66%
0.34 [0.01-8.07]
no recov.
0/38
1/40
Tehrani (RCT)
47%
0.53 [0.10-2.71]
no recov.
2/38
4/40
Tehrani (RCT)
30%
0.70 [0.45-1.10]
no recov.
16/38
24/40
Tehrani (RCT)
7%
0.93 [0.75-1.15]
no recov.
30/38
34/40
Tehrani (RCT)
21%
0.79 [0.30-2.06]
no recov.
6/38
8/40
Tehrani (RCT)
38%
0.62 [0.33-1.18]
no recov.
10/38
17/40
Abdulrahman (ICU)
3%
0.97 [0.81-1.18]
death
74/193
593/1,506
ICU patients
Acar Sevinc (ICU)
16%
0.84 [0.62-1.12]
death
57/85
12/15
ICU patients OT1
Acar Sevinc (ICU)
10%
0.90 [0.67-1.19]
ventilation
61/85
12/15
ICU patients OT1
Tawfik
96%
0.04 [0.00-0.26]
death
1/103
17/62
Tawfik
21%
0.79 [0.45-1.40]
ICU
21/103
16/62
Tawfik
16%
0.84 [0.80-0.88]
hosp. time
102 (n)
58 (n)
Babayigit
-184%
2.84 [1.27-6.14]
ventilation
47/325
17/977
Babayigit
-181%
2.81 [1.66-4.62]
ICU
75/325
35/969
Babayigit
-100%
2.00 [1.33-3.02]
hosp. time
265 (n)
746 (n)
Behboodikhah
68%
0.32 [0.05-1.83]
death
95 (n)
2,079 (n)
PIONEER
Shah (RCT)
26%
0.74 [0.44-1.23]
death
26/251
34/248
PIONEER
Shah (RCT)
24%
0.76 [0.49-1.16]
ventilation
251 (n)
248 (n)
PIONEER
Shah (RCT)
6%
0.94 [0.79-1.12]
no recov.
251 (n)
248 (n)
Alosaimi (PSM)
80%
0.20 [0.01-4.03]
death
0/37
2/37
OT1
Alosaimi (PSM)
-75%
1.75 [0.20-15.6]
hosp. time
37 (n)
37 (n)
OT1
Alosaimi (PSM)
-40%
1.40 [0.21-9.26]
no disch.
37 (n)
37 (n)
OT1
Delen
23%
0.77 [0.19-3.20]
ICU
3/34
4/35
Delen
88%
0.12 [0.02-0.91]
no recov.
1/21
8/21
Delen
-2%
1.02 [0.90-1.16]
hosp. time
34 (n)
35 (n)
Delen
-3%
1.03 [0.88-1.21]
no disch.
31/34
31/35
Hartantri
76%
0.24 [0.11-0.54]
death
n/a
n/a
Hartantri
60%
0.40 [0.17-0.98]
death
n/a
n/a
Alshamrani (PSM)
-14%
1.14 [0.96-1.35]
death
326/1,159
316/1,380
Alshamrani (PSM)
-2%
1.02 [0.86-1.20]
progression
475/1,159
499/1,380
Alshamrani (PSM)
-19%
1.19 [1.05-1.34]
ICU
668 (n)
633 (n)
Alshamrani (PSM)
-29%
1.29 [1.11-1.50]
hosp. time
1,159 (n)
1,380 (n)
Arfijanto
51%
0.49 [0.26-0.94]
viral+
8/37
55/125
Sulaiman (ICU)
-17%
1.17 [0.73-1.87]
death
73 (n)
73 (n)
ICU patients
Sulaiman (ICU)
14%
0.86 [0.53-1.39]
death
73 (n)
73 (n)
ICU patients
Sulaiman (ICU)
-47%
1.47 [1.11-1.95]
ventilation time
73 (n)
73 (n)
ICU patients
Sulaiman (ICU)
-50%
1.50 [1.10-2.04]
ICU
73 (n)
73 (n)
ICU patients
Shamsi
96%
0.04 [0.00-3.01]
death
0/19
24/164
FAVID
Horcajada (DB RCT)
-383%
4.83 [0.24-95.1]
death
2/23
0/21
FAVID
Horcajada (DB RCT)
-37%
1.37 [0.25-7.41]
ventilation
3/23
2/21
FAVID
Horcajada (DB RCT)
17%
0.83 [0.40-1.74]
recov. time
23 (n)
21 (n)
FAVID
Horcajada (DB RCT)
-125%
2.25 [0.21-23.7]
viral time
23 (n)
21 (n)
Alsaraj (RCT)
-87%
1.87 [0.67-5.21]
death
9/51
5/53
Saito
-168%
2.68 [0.96-7.48]
death
7/40
6/92
PRINCIPLE
Hobbs (RCT)
86%
0.14 [0.01-2.65]
death
0/1,829
3/1,668
PRINCIPLE
Hobbs (RCT)
-191%
2.91 [0.12-71.4]
ICU
1/1,825
0/1,663
PRINCIPLE
Hobbs (RCT)
1%
0.99 [0.61-1.61]
death/hosp.
1,829 (n)
3,256 (n)
PRINCIPLE
Hobbs (RCT)
17%
0.83 [0.73-0.94]
no recov.
350/1,582
378/1,412
PRINCIPLE
Hobbs (RCT)
12%
0.88 [0.78-0.99]
no recov.
378/1,503
384/1,340
PRINCIPLE
Hobbs (RCT)
17%
0.83 [0.74-0.92]
no recov.
418/1,507
459/1,370
PRINCIPLE
Hobbs (RCT)
29%
0.71 [0.53-0.95]
no recov.
1,829 (n)
1,668 (n)
PRINCIPLE
Hobbs (RCT)
19%
0.81 [0.75-0.88]
no recov.
1,829 (n)
3,256 (n)
PRINCIPLE
Hobbs (RCT)
34%
0.66 [0.58-0.75]
no recov.
1,828 (n)
1,666 (n)
PRINCIPLE
Hobbs (RCT)
25%
0.75 [0.69-0.83]
no recov.
1,829 (n)
1,668 (n)
PRINCIPLE
Hobbs (RCT)
12%
0.88 [0.81-0.94]
no recov.
1,562 (n)
1,407 (n)
PRINCIPLE
Hobbs (RCT)
21%
0.79 [0.73-0.86]
no recov.
1,562 (n)
1,407 (n)
PRINCIPLE
Hobbs (RCT)
23%
0.77 [0.72-0.83]
no recov.
1,828 (n)
1,667 (n)
Favipiravir COVID-19 outcomes
c19 early .org
October 2024
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors favipiravir
Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit